KMT2A and acute myeloid leukemia: Collectively, our work suggests that exogenous factors like TPO can increase the susceptibility of EVI1+ HSC for malignant transformation by KMT2A fusion oncogenes like KMT2A-MLLT3, resulting in aggressive AML expressing distinct HSC genes that may serve as biomarkers and/or future therapeutic targets.